Related Experiment Videos
Myelodysplastic (preleukemia) syndromes: the bone marrow factory failure problem
1Division of Hematology, Mayo Clinic Rochester, MN 55905, USA.
Mayo Clinic Proceedings
|July 1, 1995
Summary
Myelodysplastic syndromes (MDS) are blood disorders affecting blood cell counts. Diagnosis has improved, classifying MDS into five types, with supportive care and emerging growth factor therapies offering future hope.
Area of Science:
- Hematology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective hematopoiesis, leading to cytopenias.
- The exact etiology of MDS remains unknown, but advancements in diagnostics have improved disease classification.
Purpose of the Study:
- To outline the current understanding and classification of myelodysplastic syndromes.
- To discuss diagnostic criteria, patient assessment, and management strategies for MDS.
Main Methods:
- Review of diagnostic techniques for identification and classification of MDS.
- Assessment of cytogenetic abnormalities in MDS patients.
- Evaluation of current and investigational management approaches.
Main Results:
- MDS are classified into five categories: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.
- Cytogenetic abnormalities are observed in over 55% of MDS patients.
- Management strategies involve supportive care, with promising investigational therapies like erythropoietin and growth factors.
Conclusions:
- Improved diagnostic techniques have refined the classification of myelodysplastic syndromes.
- Patient management requires assessment of cytopenias and age, with supportive care as the primary approach.
- Emerging therapies, including growth factors, show potential for future MDS treatment.